CO6270232A2 - Derivados de catecolamina utiles para el tratamiento de enfermedades de parkinson - Google Patents
Derivados de catecolamina utiles para el tratamiento de enfermedades de parkinsonInfo
- Publication number
- CO6270232A2 CO6270232A2 CO09149335A CO09149335A CO6270232A2 CO 6270232 A2 CO6270232 A2 CO 6270232A2 CO 09149335 A CO09149335 A CO 09149335A CO 09149335 A CO09149335 A CO 09149335A CO 6270232 A2 CO6270232 A2 CO 6270232A2
- Authority
- CO
- Colombia
- Prior art keywords
- group
- compound according
- catecolamine
- derivatives
- useful
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 abstract 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 abstract 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 2
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 abstract 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003452 oxalyl group Chemical group *C(=O)C(*)=O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/08—Aza-anthracenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Portable Nailing Machines And Staplers (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200701250 | 2007-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6270232A2 true CO6270232A2 (es) | 2011-04-20 |
Family
ID=39877715
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09149335A CO6270232A2 (es) | 2007-08-31 | 2009-12-30 | Derivados de catecolamina utiles para el tratamiento de enfermedades de parkinson |
| CO10023455A CO6260082A2 (es) | 2007-08-31 | 2010-02-26 | Derivados de catecolamina utiles para el tratamiento de enfermedad de parkinson |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10023455A CO6260082A2 (es) | 2007-08-31 | 2010-02-26 | Derivados de catecolamina utiles para el tratamiento de enfermedad de parkinson |
Country Status (29)
| Country | Link |
|---|---|
| EP (4) | EP3009437A1 (enExample) |
| JP (4) | JP2010536890A (enExample) |
| KR (3) | KR101597367B1 (enExample) |
| CN (3) | CN101842354A (enExample) |
| AR (2) | AR068045A1 (enExample) |
| AU (2) | AU2008291426B2 (enExample) |
| BR (2) | BRPI0813456A2 (enExample) |
| CA (2) | CA2697688A1 (enExample) |
| CL (2) | CL2008002564A1 (enExample) |
| CO (2) | CO6270232A2 (enExample) |
| CY (1) | CY1117326T1 (enExample) |
| DK (1) | DK2197883T3 (enExample) |
| EA (2) | EA018413B1 (enExample) |
| ES (1) | ES2557485T3 (enExample) |
| HR (1) | HRP20151334T1 (enExample) |
| HU (1) | HUE025882T2 (enExample) |
| IL (1) | IL203080A (enExample) |
| MX (1) | MX2010002210A (enExample) |
| MY (2) | MY148948A (enExample) |
| NZ (2) | NZ583551A (enExample) |
| PL (1) | PL2197883T3 (enExample) |
| PT (1) | PT2197883E (enExample) |
| RS (1) | RS54470B1 (enExample) |
| SG (1) | SG184711A1 (enExample) |
| SI (1) | SI2197883T1 (enExample) |
| TW (2) | TWI404702B (enExample) |
| UA (2) | UA98804C2 (enExample) |
| WO (2) | WO2009026934A1 (enExample) |
| ZA (2) | ZA200909191B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI404702B (zh) * | 2007-08-31 | 2013-08-11 | Lundbeck & Co As H | 兒茶酚胺衍生物和其前藥 |
| WO2009156458A1 (en) * | 2008-06-27 | 2009-12-30 | H. Lundbeck A/S | Novel phenolic and catecholic amines and prodrugs thereof |
| US8067410B2 (en) | 2008-06-27 | 2011-11-29 | H. Lundbeck A/S | Phenolic and catecholic amines and prodrugs thereof |
| TW201036949A (en) * | 2009-02-27 | 2010-10-16 | Lundbeck & Co As H | Treatment of dyskinesia related disorders |
| TW201035054A (en) * | 2009-02-27 | 2010-10-01 | Lundbeck & Co As H | Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof |
| CR20200225A (es) * | 2017-11-24 | 2020-07-25 | H Lundbeck As | Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson |
| WO2020070099A1 (en) | 2018-10-02 | 2020-04-09 | H. Lundbeck A/S | Administration of catecholamine prodrugs in combination with a 5-ht2b antagonist |
| US11168056B2 (en) | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
| US11104697B2 (en) * | 2019-05-20 | 2021-08-31 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11111263B2 (en) * | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| CN119707810A (zh) * | 2019-05-21 | 2025-03-28 | H.隆德贝克有限公司 | 用于治疗帕金森病的新儿茶酚胺前药 |
| CN113677675B (zh) * | 2019-05-21 | 2024-07-26 | H.隆德贝克有限公司 | 用于治疗帕金森病的新儿茶酚胺前药 |
| CN113727979B (zh) * | 2019-05-21 | 2024-09-20 | H.隆德贝克有限公司 | 用于治疗帕金森病的新儿茶酚胺前药 |
| JP7696829B2 (ja) * | 2019-05-21 | 2025-06-23 | ハー・ルンドベック・アクチエゼルスカベット | パーキンソン病の治療に使用するためのカテコールアミンカルバメートプロドラッグ |
| CN114478298B (zh) * | 2020-11-12 | 2024-09-27 | 成都西岭源药业有限公司 | 一种造影剂碘佛醇的纯化方法 |
| CN116568672A (zh) * | 2020-11-17 | 2023-08-08 | H.隆德贝克有限公司 | 用于治疗帕金森病的新儿茶酚胺前药 |
| CN113620760A (zh) * | 2021-09-07 | 2021-11-09 | 张家口思睿凯科技有限公司 | 一种电子盐反应液和不饱和芳香烃类化合物的还原方法 |
| WO2025078574A1 (en) * | 2023-10-12 | 2025-04-17 | Integrative Research Laboratories Sweden Ab | NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4080456A (en) * | 1971-10-26 | 1978-03-21 | Schering Aktiengesellschaft | Diacylapomorphines |
| CH648300A5 (en) * | 1979-06-22 | 1985-03-15 | Sandoz Ag | Phenanthrene derivatives and medicaments containing them |
| US4543256A (en) * | 1982-03-17 | 1985-09-24 | Northeastern University | (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers |
| WO1990012574A1 (en) * | 1989-04-25 | 1990-11-01 | Northeastern University | Dopamine agonist compounds |
| JPH03163078A (ja) * | 1989-08-30 | 1991-07-15 | Sankyo Co Ltd | 光学活性な縮環複素環化合物及びその製法 |
| TW357143B (en) * | 1995-07-07 | 1999-05-01 | Novartis Ag | Benzo[g]quinoline derivatives |
| JPH11515030A (ja) * | 1995-11-10 | 1999-12-21 | ノボ ノルディスク アクティーゼルスカブ | シス−ベンズ［ｅ］インドール化合物のエナンチオマー、これらの製造、及びドーパミン−Ｄ３受容体選択的医薬としての利用 |
| CN1241998A (zh) * | 1996-10-30 | 2000-01-19 | 伊莱利利公司 | 苯并[f]喹啉酮的合成 |
| SE0002934D0 (sv) | 2000-08-17 | 2000-08-17 | Axon Biochemicals Bv | New aporphine esters and in their use in therapy |
| SE0102036D0 (sv) | 2001-06-08 | 2001-06-08 | Axon Biochemicals Bv | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
| AR030357A1 (es) * | 2000-08-18 | 2003-08-20 | Lundbeck & Co As H | Derivados 4 -, 5 -, 6 - y 7-indol |
| US20050090518A1 (en) * | 2003-10-24 | 2005-04-28 | Nastech Pharmaceutical Company Inc. | Method for treating parkinson's disease using apomorphine and apomorphine prodrugs |
| TWI404702B (zh) * | 2007-08-31 | 2013-08-11 | Lundbeck & Co As H | 兒茶酚胺衍生物和其前藥 |
-
2008
- 2008-08-19 TW TW097131506A patent/TWI404702B/zh not_active IP Right Cessation
- 2008-08-27 AR ARP080103714A patent/AR068045A1/es not_active Application Discontinuation
- 2008-08-27 AR ARP080103713A patent/AR068044A1/es active IP Right Grant
- 2008-08-28 CA CA2697688A patent/CA2697688A1/en not_active Abandoned
- 2008-08-28 KR KR1020097027342A patent/KR101597367B1/ko not_active Expired - Fee Related
- 2008-08-28 EP EP15188376.6A patent/EP3009437A1/en not_active Withdrawn
- 2008-08-28 UA UAA201003349A patent/UA98804C2/ru unknown
- 2008-08-28 MX MX2010002210A patent/MX2010002210A/es active IP Right Grant
- 2008-08-28 MY MYPI2010000841A patent/MY148948A/en unknown
- 2008-08-28 EP EP08784473A patent/EP2195291A1/en not_active Withdrawn
- 2008-08-28 AU AU2008291426A patent/AU2008291426B2/en not_active Ceased
- 2008-08-28 BR BRPI0813456-1A2A patent/BRPI0813456A2/pt not_active Application Discontinuation
- 2008-08-28 PL PL08784472T patent/PL2197883T3/pl unknown
- 2008-08-28 WO PCT/DK2008/050214 patent/WO2009026934A1/en not_active Ceased
- 2008-08-28 SI SI200831554T patent/SI2197883T1/sl unknown
- 2008-08-28 RS RS20150874A patent/RS54470B1/sr unknown
- 2008-08-28 EA EA201070327A patent/EA018413B1/ru not_active IP Right Cessation
- 2008-08-28 HR HRP20151334TT patent/HRP20151334T1/hr unknown
- 2008-08-28 BR BRPI0815894-0A2A patent/BRPI0815894A2/pt not_active IP Right Cessation
- 2008-08-28 UA UAA201000849A patent/UA97989C2/uk unknown
- 2008-08-28 CN CN200880113440A patent/CN101842354A/zh active Pending
- 2008-08-28 ES ES08784472.6T patent/ES2557485T3/es active Active
- 2008-08-28 EP EP08784472.6A patent/EP2197883B1/en active Active
- 2008-08-28 MY MYPI20095490A patent/MY179527A/en unknown
- 2008-08-28 CN CN201710269745.1A patent/CN107253956A/zh active Pending
- 2008-08-28 JP JP2010522187A patent/JP2010536890A/ja active Pending
- 2008-08-28 EP EP13175011.9A patent/EP2662358A1/en not_active Withdrawn
- 2008-08-28 CA CA2691961A patent/CA2691961C/en active Active
- 2008-08-28 DK DK08784472.6T patent/DK2197883T3/en active
- 2008-08-28 CN CN200880023124A patent/CN101687878A/zh active Pending
- 2008-08-28 SG SG2012064408A patent/SG184711A1/en unknown
- 2008-08-28 NZ NZ583551A patent/NZ583551A/en not_active IP Right Cessation
- 2008-08-28 PT PT87844726T patent/PT2197883E/pt unknown
- 2008-08-28 KR KR1020157026863A patent/KR20150115963A/ko not_active Ceased
- 2008-08-28 AU AU2008291425A patent/AU2008291425B2/en not_active Ceased
- 2008-08-28 KR KR1020107004461A patent/KR20100051834A/ko not_active Ceased
- 2008-08-28 HU HUE08784472A patent/HUE025882T2/en unknown
- 2008-08-28 WO PCT/DK2008/050215 patent/WO2009026935A1/en not_active Ceased
- 2008-08-28 NZ NZ582379A patent/NZ582379A/en not_active IP Right Cessation
- 2008-08-28 JP JP2010522186A patent/JP5548125B2/ja not_active Expired - Fee Related
- 2008-08-28 EA EA200971107A patent/EA018011B1/ru not_active IP Right Cessation
- 2008-08-29 CL CL2008002564A patent/CL2008002564A1/es unknown
- 2008-08-29 TW TW097133076A patent/TW200914426A/zh unknown
- 2008-08-29 CL CL2008002558A patent/CL2008002558A1/es unknown
-
2009
- 2009-12-23 ZA ZA2009/09191A patent/ZA200909191B/en unknown
- 2009-12-30 CO CO09149335A patent/CO6270232A2/es active IP Right Grant
- 2009-12-31 IL IL203080A patent/IL203080A/en active IP Right Grant
-
2010
- 2010-02-26 ZA ZA2010/01422A patent/ZA201001422B/en unknown
- 2010-02-26 CO CO10023455A patent/CO6260082A2/es active IP Right Grant
-
2014
- 2014-02-06 JP JP2014021193A patent/JP2014111635A/ja active Pending
- 2014-04-17 JP JP2014085192A patent/JP5802792B2/ja not_active Expired - Fee Related
-
2015
- 2015-12-28 CY CY20151101191T patent/CY1117326T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6270232A2 (es) | Derivados de catecolamina utiles para el tratamiento de enfermedades de parkinson | |
| CL2019000986A1 (es) | 1,3 di sustituto ciclobutano o derivados de azetidina como inhibidores de prostaglandina d sintasa hematopoyética(h-pgds). | |
| CO6290658A2 (es) | Derivados de azetidina y ciclobutano como inhibidores de jack | |
| AR087301A1 (es) | Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide | |
| UY37854A (es) | Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos | |
| PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| AR112774A1 (es) | Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona | |
| CO7111284A2 (es) | Nucleósidos de espirooxetano de uracilo | |
| AR074845A1 (es) | Procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable | |
| HN2010002121A (es) | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak | |
| AR068051A1 (es) | Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer. | |
| AR060545A1 (es) | Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas | |
| UY30842A1 (es) | Derivados de n-(amino-heteroaril)-1h-pirrolopiridin-2-carboxamidas, su preparacion y su aplicacion en terapéutica | |
| CO6220963A2 (es) | Cocristales y composiciones farmaceuticas que los comprenden | |
| AR066130A1 (es) | Formas cristalinas de saxagliptina y procesos para preparar las mismas | |
| AR065880A1 (es) | Derivados fluorinados de deferiprona | |
| EA201001595A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| AR072233A1 (es) | Derivados de acido lipoico y composiciones farmaceuticas que los contienen y metodos para tratar una enfermedad | |
| EA201270216A1 (ru) | Фармацевтический состав | |
| AR072803A1 (es) | Tetrahidrocinolinas como inhibidores de la 11- beta -hsd1 para la diabetes | |
| CO6150181A2 (es) | Compuesto 6-(bencilo sustituido con heterociclo)-4-oxoquinolina y su uso como inhibidor de integrasa vih | |
| UY32004A (es) | Derivados de carbamatos de alquiltiazoles, su preparación y su aplicación en terapéutica | |
| AR106515A1 (es) | Sililfenoxiheterociclos trisustituidos y análogos | |
| AR107633A1 (es) | Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico | |
| PE20200341A1 (es) | Composiciones y compuestos terapeuticos y metodos para utilizarlos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |